Smithkline Beecham Corporation

Shifa Biomedical Corporation

Temple University

Daiamed, Inc.

Sherin Salaheldin Abdel-Meguid

Harold V Meyers

Shaker Ahmed Mousa

Nabil A Elshourbagy

Cheryl Ann Janson

Ward Whitlock Smith, Jr

Christine Marie Debouck

Jeffrey S Culp

Xiayang Qiu

Susan S Hoog

Magid A Abou-Gharbia

Jian Lin

Derk J Bergsma

Wayne Everett Childers

Peter R Young

Lei Jin

Benjamin E Blass

Thomas D Bannister

Catherine E Ellis

Jeffrey L Mooney

Yuan Zhu

Stephen Dudley Holmes

Hongfeng Deng

Rajeev Aurora

Alexander H Taylor

Michael Rynkiewicz

David T Weaver

Rogelio Martinez

Renee Louise DesJarlais

Robert Edward Babine

Yen Sen Ho

George D Rose

Zihong Gho

Pramod Pandey

Baoguang Zhao

Preston Hensley

Stephanie F Guerrera

Scott R Magee

Victor Ghidu

Stephen D Holmes

Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) nano-formulation of compounds and methods of using the same

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.

The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.

Compounds and methods for treatment of thrombosis

Chimeric, humanized and other IL-18 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Monoclonal antibody and the method of using the antibody

A novel cathepsin K crystalline stucture is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.

Method of inhibiting cathepsin K

EF-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EF-7 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Cytokine family member EF-7

Novel herpes viral protease crystalline structures are identified which have an active site formed by the three amino acids Ser, His and His. Also disclosed are methods of identifying inhibitors of these proteases and/or active sites.

Proteases compositions capable of binding to said site, and methods of

Proteases, compositions capable of binding to said site, and methods of

Growing community of inventors

Exton, PA, United States of America

Sherin Salaheldin Abdel-Meguid